TGFBR1
TGF-beta receptor type-1
As of the edition of 20 October 2026, TGFBR1 (TGF-beta receptor type-1, UniProt P36897) has 4 drugs tested at it and 5 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P36897
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 45
- Disease areas
- Cancer; Digestive system; Blood and lymph; Hormones; Bones, joints and muscles; Heart and blood vessels; Immune system; Inherited and neonatal
- Registered trials of its drugs
- 48
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Galunisertib | Active | Phase 3 | none listed |
| Vactosertib | Stopped | Phase 2 | none listed |
| GFH018 | Active | Phase 2 | none listed |
| TU2218 | Status not established | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 4 |
| Undetermined | 1 |
| Total on the list | 5 |